Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jul 24, 2019 (7 years ago)

Nitrofurantoin Monohydrate/Macrycrystals Capsules

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed dissolution specifications

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Nitrofurantoin Monohydrate/Macrycrystals Capsules, 100 mg, 100-count bottle, Rx Only, Distributed by: Alvogen, Inc. Pine Brook, NY 07058 USA, NDC 47781-303-01

Affected NDC 47781-0303-01

Compare with the code on your package — it is the most precise check available.

Drug: Nitrofurantoin

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Nitrofurantoin Monohydrate/ Macrocrystalline
Nitrofurantoin Monohydrate/Macrocrystalline
NDC 47781-0303
NITROFURANTOIN 25 mg/1; NITROFURANTOIN MONOHYDRATE 75 mg/1 Capsule
Oral
Alvogen Inc. Rx
Recalling firm
Alvogen, Inc
NDC code
47781-303-01
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1722-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Nitrofurantoin recalls

See all
Class III · Low risk

Nitrofurantoin Capsules

Failed Dissolution Specifications: Nitrofurantoin Capsules recalled due to dissolution failure at 0-time of the repackaged lot. Drug release results were above specification at 0-time.

Terminated Dissolution failure American Health Packaging NDC 68084-446-11 D-0880-2022

Other recalls by Alvogen, Inc

All 2019 recalls
Class II · Moderate risk

Levothyroxine Sodium Tablets

Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.

Ongoing Labeling / mix-up Alvogen, Inc D-0259-2026
Class I · High risk

Fentanyl Transdermal System CII

Defective delivery system - patches could be multi-stacked, adhered one on top of the other, in a single product pouch.

Ongoing Packaging defect Alvogen, Inc NDC 47781-424-47 D-0245-2025